Trial Profile
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Sitravatinib (Primary)
- Indications Bone metastases; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors MethylGene; Mirati Therapeutics
- 02 Mar 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Planned End Date changed from 1 Nov 2020 to 1 Dec 2022.
- 29 Jun 2022 Results (n=193) published in the Investigational New Drugs